Race Oncology (ASX:RAC) said that the Bellberry Human Research Ethics Committee approved its phase 1 trial of its reformulated bisantrene drug candidate RC220, in combination with doxorubicin for patients with solid tumors, according to a Friday filing with the Australian bourse.
The open-label, multi-center trial aims to evaluate the safety, tolerability, and pharmacokinetic profile of the drug candidate as a standalone treatment and in combination with doxorubicin.
It will start at Southside Cancer Care Centre in New South Wales this month, pending institutional approval, with up to nine additional sites to follow, the filing said.
Stage 1 of the trial involves dose escalation to determine the maximum tolerated combined dose (MTCD) in up to 33 patients, the filing added.
Stage 2 will expand to patients who haven't received anthracyclines, confirming safety and exploring endpoints like cardioprotection and anticancer effects, the company said.
Shares of the company rose 9% in recent Friday trade.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。